Materialise Q3 2026: Revenue Tops Estimates While Earnings Miss on Rising R&D
As seen on the 24/7 Wall St. homepage on October 28, 2026.
Revenue beat expectations while earnings missed, by design: R&D spending rose to chase Medical growth, squeezing that segment's adjusted EBITDA margin to 27.4% from 30.6%. Management reaffirmed full-year revenue and adjusted EBIT guidance even after absorbing the RapidFit and Eyewear divestitures.
Continue ReadingShow less
Materialise posted Q3 2026 revenue of $75.43 million, exceeding expectations, though as-reported revenue fell 13% year over year after the RapidFit and Eyewear divestitures. Organic revenue grew 4.9%.
GAAP EPS of $0.02 came in missing expectations, weighed down by heavier R&D investment and one-time charges including inventory impairment tied to the Eyewear asset transfer and restructuring costs.
Medical revenue rose 9.7%, but the R&D spending behind that growth narrowed Adjusted EBITDA margin to 27.4%. Management calls the compression intentional.
Sponsored
Net cash strengthened to $91.93 million while the company kept repurchasing shares, giving management room to keep funding R&D.
Materialise reaffirmed full-year 2026 revenue and Adjusted EBIT guidance despite the divestiture drag. The guidance hold is the signal investors should weigh.
Mentioned: MTLS